This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ketoprofen topical


Gel formulation of ketoprofen.

Drugs List

  • ketoprofen 2.5% gel
  • POWERGEL 2.5% gel
  • TILOKET 2.5% gel
  • Therapeutic Indications


    Non-serious arthritic pain
    Relief of pain and inflammation due to trauma


    Dose varies according to brand


    Apply to the affected area two to four times daily for up to 7 days.


    Apply to the affected area two to four times daily for up to 7 days.


    Children 12 to 18 years
    Use with caution as not all brands are licensed in this age group.

    Apply to the affected area two to four times daily for up to 7 days.


    Allergic disposition
    Children under 12 years
    History of serious hypersensitivity reactions
    Open wounds
    History of asthma
    Skin infection
    Third trimester of pregnancy

    Precautions and Warnings

    Children aged 12 to 18 years
    Exudative dermatosis
    First trimester of pregnancy
    Second trimester of pregnancy
    Severe renal impairment

    NSAIDs may provoke or exacerbate asthma
    Not all available brands are licensed for all age groups
    Advise patient to wash hands after use
    Avoid contact with eyes
    Avoid contact with mucous membranes
    Avoid occlusive dressings
    Do not apply to ano-genital areas
    Do not apply to broken skin or open pressure sores
    NSAIDs may provoke bronchospasm/urticaria in susceptible patients
    Prolonged topical application may cause sensitisation reactions
    Discontinue treatment if skin rash or other allergic reaction occurs
    Treatment should be for a maximum period of 7 days
    Advise patient on appropriate sun protection methods
    Advise patient that photosensitivity possible
    Advise patient to avoid sun/UV rays during and for 2 weeks after treatment
    Advise patients to report skin rash

    Pregnancy and Lactation


    Ketoprofen is contraindicated in the third trimester.

    Ketoprofen crosses the human placenta. Ketoprofen has been associated with spontaneous abortion, although the risk appears to be small. If ketoprofen is used in the third trimester it is known to; interfere with the closure of the ductus arteriosus, inhibit labour and prolong pregnancy, and suppress the foetal renal function. Persistent pulmonary hypertension of the newborn may occur if ketoprofen is used late in pregnancy (Briggs, 2011).

    The manufacturer recommends that ketoprofen should be avoided during pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Ketoprofen should be used with caution during breastfeeding. At the time of writing, there is no published experience concerning the use of ketoprofen during breastfeeding.

    Ketoprofen is known to be excreted into breast milk in trace amounts.

    The infant should be monitored for gastro-intestinal symptoms, including diarrhoea and cramping, if ketoprofen is used by the mother.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Acute renal failure
    Anaphylactic reaction
    Bullous dermatoses
    Burning sensation (local)
    Erythema at application site
    Eyelid oedema
    Gastro-intestinal symptoms
    Gastrointestinal bleeding
    Hypersensitivity reactions
    Oedema of the lips
    Peptic ulceration
    Renal impairment
    Skin exfoliation
    Skin photosensitivity
    Skin reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2013

    Reference Sources

    British National Formulary, 65th Edition (March - September 2013) Pharmaceutical Press, London.

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Oruvail Gel 2.5%. Sanofi. Revised July 2014.
    Summary of Product Characteristics: Powergel 2.5% gel. A.Menarini Farmaceutica Internazionale SRL. Revised February 2013.
    Summary of Product Characteristics: Tiloket Gel 2.5%. Tillomed Laboratories Ltd. Revised May 2015.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Ketoprofen Last revised: June 16, 2008
    Last accessed: July 9, 2013

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.